

Single Agent Samba? Doublet Dance? Mambo Combo? Mastering the Rhythm of Treatment Selection and Sequencing in Renal Cell Carcinoma – Tweetorial #2

References

Tweet 3

SEER*Explorer. An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed October 7, 2021. <https://seer.cancer.gov/explorer/>

SEER. Cancer stat facts: kidney and renal pelvis cancer. National Cancer Institute. Accessed October 6, 2021. <https://seer.cancer.gov/statfacts/html/kidrp.html>

Tweet 4

Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. *Nat Rev Dis Primers*. 2017;3:17009. doi:10.1038/nrdp.2017.9

Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. *Cancer Cell Microenviron*. 2015;2(1):e677. doi:10.14800/ccm.677

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. *J Hematol Oncol*. 2019;12:27. doi:10.1186/s13045-019-0718-5

Zhou X, Hou W, Gao L, Shui L, Yi C, Zhu H. Synergies of antiangiogenic therapy and immune checkpoint blockade in renal cell carcinoma: from theoretical background to clinical reality. *Front Oncol*. 2020;10:1321. doi:10.3389/fonc.2020.01321

Tweet 5

Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol*. 2015;16(15):1473-1482. doi:10.1016/S1470-2045(15)00290-9

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. *J Hematol Oncol*. 2019;12:27. doi:10.1186/s13045-019-0718-5

Tweet 6

Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2015;373(19):1803-13. doi:10.1056/NEJMoa1510665

Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. *Nat Rev Dis Primers*. 2020;6:38. doi:10.1038/s41572-020-0160-6

Rini BI, Battle D, Figlin RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). *J Immunother Cancer*. 2019;7:354. doi:10.1186/s40425-019-0813-8

Zhou X, Hou W, Gao L, Shui L, Yi C, Zhu H. Synergies of antiangiogenic therapy and immune checkpoint blockade in renal cell carcinoma: from theoretical background to clinical reality. *Front Oncol.* 2020;10:1321. doi:10.3389/fonc.2020.01321

Tweet 7

Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open.* 2020;5(6):e001079. doi:10.1136/esmoopen-2020-001079

McDermott DF, Lee JL, Bjarnason GA, et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. *J Clin Oncol.* 2021;39(9):1020-1028. doi:10.1200/JCO.20.02363

Motzer RJ, Tannir NM, McDermott DF, et al. 661P conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). *Ann Oncol.* 2021;32:S685-S687. doi:10.1016/j.annonc.2021.08.057

Tweet 9

Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. *Cancer Cell Microenviron.* 2015;2(1):e677. doi:10.14800/ccm.677

Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. *Nat Rev Clin Oncol.* 2018;15(5):310-324. doi:10.1038/nrclinonc.2018.9

Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. *Ther Adv Med Oncol.* 2020;12:1758835920907504. doi:10.1177/1758835920907504

Zhou X, Hou W, Gao L, Shui L, Yi C, Zhu H. Synergies of antiangiogenic therapy and immune checkpoint blockade in renal cell carcinoma: from theoretical background to clinical reality. *Front Oncol.* 2020;10:1321. doi:10.3389/fonc.2020.01321

Tweet 11

Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open.* 2020;5(6):e001079. doi:10.1136/esmoopen-2020-001079

Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. *Ann Oncol.* 2020;31(8):1030-1039. doi:10.1016/j.annonc.2020.04.010

Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med.* 2021;384(9):829-841. doi:10.1056/NEJMoa2026982

Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. *N Engl J Med.* 2021;384(14):1289-1300. doi:10.1056/NEJMoa2035716

Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2020;21(12):1563-1573. doi:10.1016/s1470-2045(20)30436-8

Rini BI, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. *J Clin Oncol*. 2021;39(15_suppl):4500. doi:10.1200/JCO.2021.39.15_suppl.4500

Choueiri TK, Powles T, Porta C, et al. A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (the CLEAR study). Presented at: Kidney Cancer Research Summit; 2021; Philadelphia, PA, USA. Accessed October 19, 2021. <https://kcrs.kidneycan.org/wp-content/uploads/2021/10/Abstracts-Book-KCRS-2021-v2-10112021.pdf>

Glossary

aRCC, advanced renal cell carcinoma
Axi, axitinib
Cabo, cabozantinib
CTLA-4, cytotoxic T lymphocyte-associated antigen-4
FGF, fibroblast growth factor
FGFR, fibroblast growth factor receptor
HGF, hepatocyte growth factor
HR, hazard ratio
HRE, hypoxia response element
IFN, interferon
IO, immunotherapy
I/P, intermediate/poor
ITT, intent to treat
Len, lenvatinib
MET, mesenchymal epithelial transition
MHC, major histocompatibility complex
MOA, mechanism of action
NA, not applicable
NCCN, National Comprehensive Cancer Network
NE, not estimable
NK, natural killer
Nivo, nivolumab
NR, not reported
ORR, overall response rate
OS, overall survival
PDGFR, platelet-derived growth factor receptor
PD-1, programmed cell death protein 1
PD-L1, programmed death-ligand 1
Pembro, pembrolizumab
PFS, progression-free survival
RCC, renal cell carcinoma
SEER, Surveillance, Epidemiology, and End Results Program
SOC, standard of care
TCR, T-cell receptor
TKI, tyrosine kinase inhibitor
VEGF, vascular endothelial growth factor
VEGFR, vascular endothelial growth factor receptor
w/, with